Key Insights

Highlights

Success Rate

82% trial completion

Published Results

91 trials with published results (14%)

Research Maturity

294 completed trials (46% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

10.4%

66 terminated out of 635 trials

Success Rate

81.7%

-4.8% vs benchmark

Late-Stage Pipeline

15%

94 trials in Phase 3/4

Results Transparency

31%

91 of 294 completed with results

Key Signals

91 with results82% success66 terminated

Data Visualizations

Phase Distribution

382Total
Not Applicable (144)
Early P 1 (6)
P 1 (45)
P 2 (93)
P 3 (60)
P 4 (34)

Trial Status

Completed294
Recruiting93
Unknown93
Terminated66
Withdrawn34
Not Yet Recruiting27

Trial Success Rate

81.7%

Benchmark: 86.5%

Based on 294 completed trials

Clinical Trials (635)

Showing 20 of 20 trials
NCT03626688Phase 3Completed

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

NCT01730092Recruiting

Natural History Study of Biomarkers in Pulmonary Arterial Hypertension

NCT07073820Phase 2RecruitingPrimary

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

NCT05896579Not ApplicableRecruiting

Right Ventricular Response to Exercise Among Patients With Chronic Obstructive Pulmonary Disease

NCT07179380Phase 3RecruitingPrimary

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT00011648CompletedPrimary

Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia

NCT07224906RecruitingPrimary

Observational Study of Patients Undergoing Diagnostic Right Heart Catheterization

NCT05612035Phase 2Active Not RecruitingPrimary

Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

NCT00678821Phase 2CompletedPrimary

Aerobic Exercise in Patients With Pulmonary Hypertension

NCT06911632Not ApplicableActive Not RecruitingPrimary

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

NCT06770023Phase 1Recruiting

Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension

NCT07495774RecruitingPrimary

Insights Into Pediatric Pulmonary Hypertension: A Real-World Registry of Epidemiology and Outcomes

NCT06616974Phase 2RecruitingPrimary

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

NCT06373289Not ApplicableRecruiting

Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants

NCT07487441Not Yet Recruiting

Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.

NCT07481877Not Yet Recruiting

Portosystemic Shunt-associated Pulmonary Hypertension Multi-center Prospective Cohort Study

NCT03854071Not ApplicableRecruiting

Development of Novel Physiological CMR Methods in Health and Disease

NCT01961232Active Not RecruitingPrimary

Trans-pulmonary Biomarkers in Pulmonary Hypertension

NCT07477197Recruiting

Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders

NCT07214376Not ApplicableNot Yet RecruitingPrimary

A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

Scroll to load more

Research Network

Activity Timeline